These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23123015)

  • 1. Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.
    Miyamoto N; Oguro Y; Takagi T; Iwata H; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2012 Dec; 20(24):7051-8. PubMed ID: 23123015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
    Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.
    Shimizu H; Tanaka S; Toki T; Yasumatsu I; Akimoto T; Morishita K; Yamasaki T; Yasukochi T; Iimura S
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5113-8. PubMed ID: 20675134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
    Okaniwa M; Hirose M; Imada T; Ohashi T; Hayashi Y; Miyazaki T; Arita T; Yabuki M; Kakoi K; Kato J; Takagi T; Kawamoto T; Yao S; Sumita A; Tsutsumi S; Tottori T; Oki H; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    J Med Chem; 2012 Apr; 55(7):3452-78. PubMed ID: 22376051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor.
    Miyamoto N; Sakai N; Hirayama T; Miwa K; Oguro Y; Oki H; Okada K; Takagi T; Iwata H; Awazu Y; Yamasaki S; Takeuchi T; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Apr; 21(8):2333-2345. PubMed ID: 23498918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of naphthalene imidazo[1,2-b]pyridazine hybrid derivatives as VEGFR selective inhibitors.
    Wang S; Gan L; Han L; Deng P; Li Y; He D; Chi H; Zhu L; Li Y; Long R; Gan Z
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400411. PubMed ID: 39008876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
    Hirose M; Okaniwa M; Miyazaki T; Imada T; Ohashi T; Tanaka Y; Arita T; Yabuki M; Kawamoto T; Tsutsumi S; Sumita A; Takagi T; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Sep; 20(18):5600-15. PubMed ID: 22883026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.
    Shimizu H; Yasumatsu I; Hamada T; Yoneda Y; Yamasaki T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
    Bioorg Med Chem Lett; 2011 Feb; 21(3):904-8. PubMed ID: 21232950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.
    Oguro Y; Miyamoto N; Okada K; Takagi T; Iwata H; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
    Bioorg Med Chem; 2010 Oct; 18(20):7260-73. PubMed ID: 20833055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
    Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities.
    Jaballah MY; Serya RAT; Saad N; Khojah SM; Ahmed M; Barakat K; Abouzid KAM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1573-1589. PubMed ID: 31852269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation.
    Hamdouchi C; Sanchez-Martinez C; Gruber J; Del Prado M; Lopez J; Rubio A; Heinz BA
    J Med Chem; 2003 Sep; 46(20):4333-41. PubMed ID: 13678411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
    Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.